Vicore Pharma to Participate in the Leerink Therapeutics Forum

Rhea-AI Summary

Vicore Pharma (NASDAQ:VCRE), a clinical-stage biopharmaceutical company developing angiotensin II type 2 receptor agonists (ATRAGs), will participate in the Leerink Therapeutics Forum.

The event will be held on Tuesday, July 14, 2026, at the Boston Harbor Hotel in Boston, Massachusetts, and will feature 1×1 investor meetings with CEO Ahmed Mousa.

Market reaction after Leerink Therapeutics Forum participation: VCRE -7.54% in the Jul 7 session

-7.54% 6.1x vol

19 alerts

-7.54% Session close to close

+33.5% Peak Tracked

-33.0% Trough Tracked

$4.57B Market Cap

6.1x Rel. Volume

In the Jul 7 session, VCRE declined 7.54%, reflecting a notable negative market reaction. Argus tracked a peak move of +33.5% during that session. Argus tracked a trough of -33.0% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. Trading volume was exceptionally heavy at 6.1x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -7.5% in the session following this news. A sharp downside move despite this routine...

Analysis

The stock moved -7.5% in the session following this news. A sharp downside move despite this routine forum participation would contrast with the low-key nature of the news and VCRE’s position only 1.69% under its 52‑week high, suggesting investor sensitivity to broader pipeline or funding concerns rather than the conference itself.

Key Figures

Conference date: July 14, 2026

1 metrics

Conference date July 14, 2026 Leerink Therapeutics Forum participation

Key Terms

angiotensin ii type 2 receptor agonists (atrags)

1 terms

angiotensin ii type 2 receptor agonists (atrags) medical

"a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today"

Angiotensin II type 2 receptor agonists (ATRAGs) are drugs designed to bind and activate the type 2 angiotensin receptor, a protein involved in regulating blood vessel tone, inflammation, tissue repair and fluid balance. Think of them as a specific key that turns on a particular biological switch with the aim of reducing fibrosis, lowering blood pressure or modulating inflammatory responses. They matter to investors because their clinical trial results, regulatory status and market potential can materially affect the value and prospects of companies developing them.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, SE / ACCESS Newswire / July 7, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company will participate in the Leerink Therapeutics Forum.

Location: Boston Harbor Hotel, Boston, Mass.
Format: 1×1 meetings
Date: Tuesday, July 14, 2026
Participant: Ahmed Mousa, CEO

For more information, please contact:
Megan Richards, VP of IR and Comms, +1 978 269-4372, megan.richards@vicorepharma.com
Hans Jeppsson, CFO, +46 70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small molecule angiotensin II type 2 receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements concerning Vicore Pharma and its listing and trading of ADSs on Nasdaq. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, references to novel drugs and those risks identified in the section entitled "Risk Factors" in Vicore Pharma's filings the U.S. Securities and Exchange Commission and discussed in Vicore Pharma's Swedish filings, its press releases, and the Registration Statements. Vicore Pharma cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Vicore Pharma disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent Vicore Pharma's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Attachments
Vicore Pharma to Participate in the Leerink Therapeutics Forum

SOURCE: Vicore Pharma Holding

View the original press release on ACCESS Newswire

FAQ

When will Vicore Pharma (VCRE) attend the Leerink Therapeutics Forum in 2026?

Vicore Pharma will attend the Leerink Therapeutics Forum on Tuesday, July 14, 2026. The event takes place at the Boston Harbor Hotel in Boston, Massachusetts, and focuses on 1×1 meetings with investors and stakeholders.

Where is the 2026 Leerink Therapeutics Forum with Vicore Pharma (VCRE) being held?

The 2026 Leerink Therapeutics Forum featuring Vicore Pharma is at the Boston Harbor Hotel in Boston, Massachusetts. According to the company, the format will be 1×1 meetings with CEO Ahmed Mousa and investors.

Who will represent Vicore Pharma (VCRE) at the Leerink Therapeutics Forum 2026?

Vicore Pharma will be represented by CEO Ahmed Mousa at the Leerink Therapeutics Forum. According to the company, Mousa will participate in 1×1 meetings with investors at the Boston Harbor Hotel on July 14, 2026.

What is the meeting format for Vicore Pharma (VCRE) at the Leerink Therapeutics Forum?

Vicore Pharma’s participation at the Leerink Therapeutics Forum will be in a 1×1 meetings format. According to the company, these sessions allow direct discussions between CEO Ahmed Mousa and institutional investors at the Boston Harbor Hotel.

How can investors contact Vicore Pharma (VCRE) investor relations about the Leerink Forum?

Investors can contact Megan Richards, VP of IR and Communications, at +1 978 269-4372 or megan.richards@vicorepharma.com. According to Vicore Pharma, Hans Jeppsson, CFO, is also available at +46 70 553 14 65 and hans.jeppsson@vicorepharma.com.

What type of company is Vicore Pharma (VCRE) presenting at the Leerink Therapeutics Forum?

Vicore Pharma is a clinical-stage biopharmaceutical company developing angiotensin II type 2 receptor agonists (ATRAGs). According to the company, these novel drugs aim to unlock new therapeutic potential, making investor meetings at the Leerink Therapeutics Forum relevant.